Details for Patent: 12,692,251
Which drugs does patent 12,692,251 protect, and when does it expire?
Patent 12,692,251 protects GAVRETO and is included in one NDA.
This patent has fourteen patent family members in fourteen countries.
Summary for Patent: 12,692,251
| Title: | Pralsetinib pharmaceutical compositions |
| Abstract: | The present disclosure relates to pharmaceutical composition comprising 1) an amorphous solid dispersion comprising pralsetinib, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable hydrophilic polymer; and 2) an effervescent couple; and crystalline forms of pralsetinib and pralsetinib hydrochloride salt, which are useful as a RET selective inhibitors. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders. |
| Inventor(s): | Joshua Waetzig, Gordon D. Wilkie, Debra L. Mazaik, Csanad M. Varga, Lia Rogal, Lauren MacEachern, Kimberly Jean Miller, Shellie Rigby-Singleton, Ian A. Barker, Robert J. Harris, Aimee J. Spenceley, Dipak Gordhan |
| Assignee: | Catalent Nottingham Ltd , Rigel Pharmaceuticals Inc |
| Application Number: | US18/000,166 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; |
Drugs Protected by US Patent 12,692,251
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharms | GAVRETO | pralsetinib | CAPSULE;ORAL | 213721-001 | Sep 4, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,692,251
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021281283 | ⤷ Start Trial | |||
| Brazil | 112022024374 | ⤷ Start Trial | |||
| Canada | 3184648 | ⤷ Start Trial | |||
| Chile | 2022003353 | ⤷ Start Trial | |||
| China | 116133646 | ⤷ Start Trial | |||
| Costa Rica | 20220666 | ⤷ Start Trial | |||
| European Patent Office | 4157230 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
